Elevated expression and altered processing of fibulin-I protein in human breast cancer

British Journal of Cancer

Volumn 88, Issue 6, 2003, Pages 871-878

  Greene, L M ^a   Twal, W O ^b   Duffy, M J ^c   McDermott, E W ^c   Hill, A D ^c   O'Higgins, N J ^c   McCann, A H ^a,d   Dervan, P A ^a,d   Argraves, W S ^b   Gallagher, W M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d MATER PRIVATE HOSPITAL   (Ireland)

Author keywords

Breast cancer; Extracellular matrix; Fibulin; Oestrogen receptor; Proteolysis

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; FIBULIN; FIBULIN 1; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CELL INVASION; CELL MOTILITY; CELL TYPE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; EPITHELIUM CELL; EPITOPE MAPPING; EXTRACELLULAR MATRIX; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR SIZE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; QUANTITATIVE DIAGNOSIS; RANK SUM TEST; TISSUE SPECIFICITY;

ANTIBODIES, MONOCLONAL; BREAST; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ESTROGEN;

EID: 0242584510     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600802     Document Type: Article

References (33)

1. Akiyama SK, Olden K, Yamada KM (1995) Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14: 173-189
2. Argraves WS, Tran H, Burgess WH, Dickerson K (1990) Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. J Cell Biol 111: 3155-3164
3. Balbona K, Tran H, Godyna S, Ingham KC, Strickland DK, Argraves WS (1992) Fibulin binds to itself and to the carboxyl-terminal heparin-binding region of fibronectin. J Biol Chem 267: 20 120-20 125
4. Chapman JW, Mobbs BG, McCready DR, Lickley HL, Trudeau ME, Hanna W, Kahn HJ, Sawka CA, Fish EB, Pritchard KI (1996) An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays. J Steroid Biochem Mol Biol 57: 323-328
5. Clinton GM, Rougeot C, Derancourt J, Roger P, Defrenne A, Godyna S, Argraves WS, Rochefort H (1996) Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci USA 93: 316-320
6. Cullen R, Maguire TNI, McDermott EW, Hill AD, O'Higgins NJ, Duffy MJ (2001) Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer. Eur J Cancer 37: 1118-1122
7. Debeer P, Schoenmakers EF, Twal WO, Argraves WS, De Smet L, Fryns JP, Van De Ven WJ (2002) The fibulin-1 gene (FBLN1) is disrupted in a t(12;22) associated with a complex type of synpolydactyly. J Med Genet 39: 98-104
8. Devleeschouwer N, Legros N, Olea-Serrano N, Paridaens R, Leclercq G (1987) Estrogen conjugates and serum factors mediating the estrogenic trophic effect on MCF-7 cell growth. Cancer Res 47: 5883-5887
9. Forti S, Scanlan MJ, Invernizzi A, Castiglioni F, Pupa S, Agresti R, Fontanelli R, Morelli D, Old LJ, Pupa SNI, Menard S (2002) Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum. Breast Cancer Res Treat 73: 245-256
10. Giese A, Loo MA, Norman SA, Treasurywala S, Berens ME (1996) Contrasting migratory response of astrocytoma cells to tenascin mediated by different integrins. J Cell Sci 109: 2161-2168
11. Greenwood JA, Murphy-Ullrich JE (1998) Signaling of de-adhesion in cellular regulation and motility. Microsc Res Technol 43: 420-432
12. Hayashido Y, Lucas A, Rougeot C, Godyna S, Argraves WS, Rochefort H (1998) Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin. Int J Cancer 75: 654-658
13. Hirosaki T, Mizushima H, Tsubota Y, Moriyama K, Miyazaki K (2000) Structural requirement of carboxyl-terminal globular domains of laminin alpha 3 chain for promotion of rapid cell adhesion and migration by laminin-5. J Biol Chem 275: 22 495-22 502
14. Hurd C, Nag K, Khattree N, Alban P, Dinda S, Moudgil VK (1999) Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells. Mol Cell Biochem 199: 49-56
15. Ishihara A, Yoshida T, Tamaki H, Sakakura T (1995) Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1: 1035-1041
16. Iwasaki K, Underwood B, Herman M, Dinda S, Kodali S, Kloosterboer HJ, Hurd C, Moudgil VK (1999) Effects of antiprogestins on the rate of proliferation of breast cancer cells. Mol Cell Biochem 198: 141-149
17. Jahkola T, Toivonen T, von Smitten K, Blomqvist C, Virtanen I (1996) Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 69: 445-447
18. Kao RT, Stern R (1986) Elastases in human breast carcinoma cell lines. Cancer Res 46: 1355-1358
19. Koukoulis GK, Howeedy AA, Korhonen M, Virtanen I, Gould VE (1993) Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J Submicrosc Cytol Pathol 25: 285-295
20. Kusubata M, Hirota A, Ebihara T, Kuwaba K, Matsubara Y, Sasaki T, Kusakabe NI, Tsukada T, Irie S, Koyama Y (1999) Spatiotemporal changes of fibronectin, tenascin-C, fibulin-1, and fibulin-2 in the skin during the development of chronic contact dermatitis. J Invest Dermatol 113: 906-912
21. Loridon-Rosa B, Vielh P, Cuadrado C, Burtin P (1988) Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. Am J Clin Pathol 90: 7-16
22. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y, Sakakura T (1987) Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 84: 4621-4625
23. Martin KJ, Kwan CP, Nagasaki K, Zhang X, O'Hare NIJ, Kaelin CM, Burgeson RE, Pardee AB, Sager R (1988) Down-regulation of laminin-5 in breast carcinoma cells. Mol Med 4: 602-613
24. Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H, Pujol P (2002) Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 21: 1097-1107
25. Qing J, Maher VM, Tran H, Argraves WS, Dunstan RW, McCormick JJ (1997) Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. Oncogene 15: 2159-2168
26. Roger P, Pujol P, Lucas A, Baldet P, Rochefort H (1998) Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. Am J Pathol 153: 1579-1588
27. Romberger DJ (1997) Fibronectin. Int J Biochem Cell Biol 29: 939-943
28. Sasaki T, Mann K, Murphy G, Chu ML, Timpl R (1996) Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases. Eur J Pathol 240: 427-434
29. Takei H, Iino Y, Horiguchi J, Yokoe T (1995) Immunohistochemical fibronectin staining pattern and prognosis in invasive breast carcinoma. Oncology 52: 106-111
30. Takei H, Iino Y, Horiguchi J, Maemura NI, Koibuchi Y, Nagaoka H, Yokoe T, Oyama T, Morishita Y (1998) Angiogenesis and stromal fibronectin expression in invasive breast carcinoma. Int J Oncol 12: 517-523
31. Tran H, Mattei M, Godyna S, Argraves WS (1997) Human fibulin-1D: molecular cloning, expression and similarity with S1-5 protein, a new member of the fibulin gene family. Matrix Biol 15: 479-493
32. Twal WO, Czirok A, Hegedus B, Knaak C, Chintalapudi MR, Okagawa H, Sugi Y, Argraves WS (2001) Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 114: 4587-4598
33. Vasishta A, Baker PR, Preece PE, Wood RA, Cuschieri A (1989) Proteinase-like peptidase activities and oestrogen receptor levels in breast cancer tissue. J Cancer Res Clin Oncol 115: 89-92